The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …

Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …

Introduction Lung cancer in never-smokers is the major cancer cause of death globally. We
compared the efficacy of low-dose computed tomography (LDCT) lung cancer screening …

Importance Despite a growing population of survivors of lung cancer, there is limited
understanding of the survivorship journey. Survivors of lung cancer experience unmet …

ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9–2.6% of patients with non
small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine …

Purpose This study aimed to develop and validate a specific risk-stratification nomogram
model for the prediction of venous thromboembolism (VTE) in hospitalized patients with lung …

Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …

Simple Summary Thrombotic events are a common problem for lung cancer patients.
Compared to other types of cancer, lung cancer patients are more likely to experience blood …

Introduction: Glioblastoma (GBM) patients have a 20–30 incidence of venous
thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent …

ROS1 rearrangement is found in 0.9%–2.6% of people with non-small-cell lung cancers
(NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and …